Core Viewpoint - Burning Rock Biotech Limited's founder and CEO, Mr. Yusheng Han, has demonstrated confidence in the company's future by purchasing approximately US$811,721.28 worth of the company's American Depositary Shares (ADSs) from the open market [1]. Group 1: Company Actions - Mr. Han's purchase of the company's ADSs was conducted in compliance with applicable rules and regulations, as well as the company's insider trading policy [1]. - There is potential for Mr. Han to continue purchasing the company's ADSs through various means, including open-market transactions and block trades, depending on market conditions [2]. Group 2: Company Overview - Burning Rock Biotech Limited focuses on the application of next generation sequencing (NGS) technology in precision oncology, with a mission to guard life via science [3]. - The company's business includes NGS-based therapy selection testing for late-stage cancer patients and cancer early detection, which has progressed to the clinical validation stage [3].

Core Viewpoint - Burning Rock Biotech Limited successfully passed all shareholder resolutions at its 2025 annual general meeting, indicating strong support for the company's strategic direction and governance [1][2]. Company Overview - Burning Rock Biotech Limited focuses on next generation sequencing (NGS) technology in precision oncology, with a mission to guard life via science [1]. - The company's business includes NGS-based therapy selection testing for late-stage cancer patients and cancer early detection, which has progressed to the clinical validation stage [1]. Shareholder Resolutions - The appointment of Ernst & Young Hua Ming LLP as the auditor for the fiscal year ending December 31, 2025, was ratified, with the directors authorized to determine the auditor's remuneration [2]. - Feng Deng and Licen Lisa Xu were re-elected as directors of the company [2]. - Each director was authorized to take necessary actions to effectuate the resolutions as deemed fit [2].